Unichem Laboratories Ltd

Unichem Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Unichem Laboratories Ltd

₹ 861 -2.36%
21 Nov - close price
unichemlabs.com BSE: 506690 NSE: UNICHEMLAB
About

Unichem Laboratories Ltd is involved in pharmaceuticals
in Generics, APIs and Contract Manufacturing (CMO) areas.[1]

Key Points

Therapeutic Areas
The company manufactures and markets APIs and pharmaceutical formulations as branded & non-branded generics. The company’s products cater to diverse therapeutic areas such as cardiology, gas, diabetology, gastroenterology psychiatry, neurology, antibacterial, anti-infective, and pain management. [1]

Website BSE NSE
  • Market Cap ₹ 6,059 Cr.
  • Current Price ₹ 861
  • High / Low ₹ 950 / 401
  • Stock P/E 121
  • Book Value ₹ 341
  • Dividend Yield 0.00 %
  • ROCE 0.39 %
  • ROE -1.17 %
  • Face Value ₹ 2.00
Edit ratios

Pros

Cons

  • Stock is trading at 2.52 times its book value
  • The company has delivered a poor sales growth of 7.64% over past five years.
  • Company has a low return on equity of -2.33% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE Allcap BSE SmallCap BSE Healthcare

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
291 311 370 310 329 302 402 423 416 434 432 446 462
284 313 302 311 347 345 386 395 407 396 406 403 405
Operating Profit 6 -1 68 -1 -18 -43 16 28 9 38 25 44 58
OPM % 2% -0% 18% -0% -6% -14% 4% 7% 2% 9% 6% 10% 12%
3 15 14 8 4 16 -28 9 6 79 -119 4 9
Interest 2 1 2 3 5 4 6 6 7 6 5 4 5
Depreciation 22 23 23 25 28 31 30 29 29 28 27 28 29
Profit before tax -16 -11 58 -21 -47 -61 -47 2 -22 84 -126 15 33
Tax % -17% 24% -23% 13% 50% 4% -6% 132% 12% -0% 3% 38% 8%
-13 -14 71 -23 -71 -64 -44 -1 -24 84 -129 9 30
EPS in Rs -1.82 -2.00 10.15 -3.32 -10.04 -9.08 -6.29 -0.10 -3.48 11.93 -18.37 1.32 4.33
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
1,081 1,133 1,202 1,333 698 815 1,180 1,104 1,235 1,270 1,343 1,705 1,775
906 956 1,100 1,169 738 942 1,254 1,153 1,144 1,198 1,389 1,605 1,610
Operating Profit 174 178 101 164 -41 -128 -74 -49 91 72 -46 100 164
OPM % 16% 16% 8% 12% -6% -16% -6% -4% 7% 6% -3% 6% 9%
13 83 20 15 184 2,735 91 91 50 47 -0 -26 -28
Interest 3 3 3 3 3 8 8 8 5 6 17 23 19
Depreciation 38 46 41 39 44 51 67 82 84 91 113 113 112
Profit before tax 146 212 77 137 97 2,548 -58 -48 51 22 -176 -62 6
Tax % 22% 20% 3% 21% -12% 0% -59% 25% 33% -50% 15% 14%
113 169 75 108 109 2,545 -24 -60 34 33 -202 -70 -6
EPS in Rs 12.52 18.68 8.31 11.90 11.96 361.82 -3.38 -8.55 4.87 4.70 -28.72 -10.01 -0.79
Dividend Payout % 36% 43% 24% 17% 25% 1% -118% -47% 82% 85% -14% 0%
Compounded Sales Growth
10 Years: 4%
5 Years: 8%
3 Years: 11%
TTM: 15%
Compounded Profit Growth
10 Years: %
5 Years: 6%
3 Years: %
TTM: 149%
Stock Price CAGR
10 Years: 14%
5 Years: 41%
3 Years: 63%
1 Year: 104%
Return on Equity
10 Years: 13%
5 Years: -2%
3 Years: -2%
Last Year: -1%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 18 18 18 18 18 14 14 14 14 14 14 14 14
Reserves 709 798 849 936 1,045 2,666 2,606 2,517 2,543 2,604 2,421 2,348 2,387
27 26 22 36 98 151 200 206 119 349 314 248 300
318 302 264 283 359 359 323 407 436 351 444 559 610
Total Liabilities 1,073 1,145 1,153 1,274 1,521 3,190 3,142 3,145 3,112 3,319 3,193 3,169 3,311
448 419 416 403 491 578 810 870 884 990 1,257 1,196 1,153
CWIP 132 91 123 237 250 238 92 330 568 494 147 123 145
Investments 39 11 41 14 14 901 926 550 392 264 2 1 0
454 623 574 620 766 1,473 1,313 1,395 1,269 1,571 1,787 1,849 2,013
Total Assets 1,073 1,145 1,153 1,274 1,521 3,190 3,142 3,145 3,112 3,319 3,193 3,169 3,311

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
171 87 78 112 68 -112 -328 20 33 -260 -85 17
-118 36 -52 -85 -132 1,648 -286 -36 -66 100 241 57
-51 -95 -51 -33 59 -881 -2 -62 -121 191 -81 -106
Net Cash Flow 1 28 -25 -7 -4 655 -616 -78 -154 32 75 -33

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 70 63 58 60 165 124 135 129 74 142 160 131
Inventory Days 132 192 171 184 397 278 278 374 518 527 414 387
Days Payable 145 142 114 131 297 230 182 236 202 161 193 164
Cash Conversion Cycle 57 113 116 113 265 172 231 267 390 508 382 353
Working Capital Days 59 95 89 94 225 200 227 217 194 277 272 217
ROCE % 20% 19% 9% 15% 9% 128% -2% -2% 2% 1% -5% 0%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
50.93% 50.93% 50.93% 50.94% 50.94% 50.94% 50.94% 70.21% 70.22% 70.22% 70.22% 70.22%
1.45% 1.47% 1.50% 1.71% 1.56% 1.70% 1.62% 0.83% 0.84% 0.90% 0.89% 0.94%
9.30% 9.59% 9.53% 8.70% 8.21% 8.15% 9.65% 10.00% 10.46% 11.26% 11.57% 11.65%
38.32% 38.01% 38.04% 38.67% 39.31% 39.21% 37.80% 18.95% 18.47% 17.63% 17.32% 17.17%
No. of Shareholders 35,31333,55732,66629,57330,61829,41826,64221,58420,87721,17120,62120,374

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls